HEALTH RETURNING TO DRUG SECTOR, SAYS S&P

Standard & Poor's Equity Research Services, a leading provider of independent investment analysis and research opinions, forecasts pharmaceutical profits to rise modestly this year, helped by improved new products flows, Medicare Part D, continued cost streamlining and a rosier picture for litigation issues. Based on these improving conditions, Standard & Poor's raised its fundamental outlook for large pharmaceutical firms to positive from neutral last week.
Drug Newswire